New treatment may reverse disease that plagues women over 65
Key Points:
- A clinical trial in Spain demonstrated that a single infusion of engineered mesenchymal stem/stromal cells (MSCs) significantly reduced fragility fractures by 94% over two years in women with advanced osteoporosis.
- The treatment increased bone tissue by 70% after four months and led to a 34% decrease in bone pain and a 30% reduction in disability, suggesting potential reversal of bone density loss.
- MSCs were collected from patients' own bone marrow, multiplied in labs, and infused back, but questions remain about whether these cells directly reach bone tissue or act via other mechanisms, such as the pancreas.
- Challenges for MSC therapy include the cells' large size causing them to lodge in the lungs and difficulty targeting bone marrow, as well as the absence of a control group and concurrent osteoporosis medications in the study.
- A follow-up trial is planned with a larger patient cohort to compare treatments using autologous MSCs, donor MSCs, or no MSC treatment to better assess efficacy and address current uncertainties.